Le Registre des lobbyistes
Innovative Medicines Canada / Médicaments novateurs Canada
Subject matters | Details | Categories |
---|---|---|
Federal-Provincial Relations, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
|
Legislative Proposal, Bill or Resolution
|
Foreign Affairs, Health, Infrastructure, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
|
Policies or Program
|
Foreign Affairs, Health, Intellectual Property, International Trade, Research and Development, Science and Technology
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
Foreign Affairs, Health, Intellectual Property, International Trade, Research and Development, Science and Technology
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
Environment, Health, Intellectual Property, Research and Development, Science and Technology
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Regulation, Legislative Proposal, Bill or Resolution
|
Health, Research and Development, Science and Technology, Taxation and Finance
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
Health, Intellectual Property, Research and Development, Science and Technology
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
Agriculture, Consumer Issues, Foreign Affairs, Health, International Relations, International Trade, Taxation and Finance
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution, Regulation
|
Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Free trade agreements as they relate to the biopharmaceutical industry
|
Policies or Program
|
Agriculture, Consumer Issues, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Income Tax Act as it relates to biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Health, Industry, Intellectual Property, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
National Strategy for Drugs for Rare Diseases
|
Policies or Program, Regulation
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Health, Research and Development, Science and Technology
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
Agriculture, Government Procurement, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
World Health Organization (WHO) issues concerning the biopharmaceutical industry
|
Policies or Program
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
|
Policies or Program
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|